Sudeep Pharma profit and loss

Latest FY26

Revenue: ₹642cr
EBITDA: ₹222cr
Net profit: ₹174cr
EPS: ₹15.50

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026

Expenses
	710	642
	24.7	28.6
	734	671
	282	270
	−31.4	−42.2
	55.5	51.9
	8.5	7.6
	17.1	14.8
	153	141
	485	443
	251	222
	234	207
Profit
	250	228
	250	228
	56.9	50.9
	4.2	2.9
	61.2	53.8
	189	174
	189	174
	3.9	−1.2
	193	173
	—	173
	—	1.4
Per share
	₹16.85	₹15.50
	₹16.85	₹15.50
Other comprehensive income — detail
	3.9	−1.2
	−0.1	−0.0
	−5.9	1.2
	192	172
	0.4	1.4
Per share — as-filed variants
	₹16.85	₹15.50
	₹16.85	₹15.50
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	459	415
	64.7%	64.6%
Adjusted (ex-exceptional items) — derived
	250	228
	189	174
	₹16.85	₹15.50

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUDEEPPHRM₹1,130.10

Sudeep Pharma Ltd.

· Chemicals

Annual Quarterly₹ CrorePeersSUDARSCHEM STYRENIX SHARDACROP REFEX RCF RALLIS RAIN PRIVISCLMcap ₹12,764 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	642.3	709.6
Other Income	28.6	24.7
Total Income	670.8	734.3
Expenses
+ Cost of Materials Consumed	269.5	281.6
+ Changes in Inventories	-42.2	-31.4
+ Employee Benefit Expense	51.9	55.5
+ Finance Costs	7.6	8.5
+ Depreciation & Amortisation	14.8	17.1
+ Other Expenses	141.2	153.3
Total Expenses	442.8	484.5
EBITDA	221.9	250.7
EBIT	207.1	233.6
Profit
PBT before Exceptional Items	228.1	249.8
Pretax Income	228.1	249.8
+ Current Tax	50.9	56.9
+ Deferred Tax	2.9	4.2
Tax Expense	53.8	61.2
Net Income	174.3	188.6
+ Net Income — Continuing Ops	174.3	188.6
+ Other Comprehensive Income	-1.2	3.9
Total Comprehensive Income	173.1	192.6
Net Income to Common	172.9	—
Minority Interest	1.4	—
Per Share
Basic EPS	15.50	16.85
Diluted EPS	15.50	16.85
Other Comprehensive Income — detail
+ Other Comprehensive Income	-1.2	3.9
+ Tax on Items NOT to be Reclassified	-0.0	-0.1
+ Tax on Items to be Reclassified	1.2	-5.9
Comprehensive Income — Owners of Parent	171.7	192.4
Comprehensive Income — Non-controlling Interests	1.4	0.4
Per Share — as-filed variants
Basic EPS — Continuing Operations	15.50	16.85
Diluted EPS — Continuing Operations	15.50	16.85
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	415.0	459.5
Gross Margin %	64.61	64.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	228.1	249.8
Net Income Adj (tax-effected)	174.3	188.6
EPS Adj	15.50	16.85
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	—
Paid Up Equity Capital	11.3	—

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.